肿瘤突变负荷对非小细胞肺癌免疫治疗疗效的预测价值  

Predictive value of tumor mutation burden in immunotherapy for non-small-cell lung cancer

作　　者：殷悦 张羽白 邢丽娜[1] YIN Yue;ZHANG Yu-Bai;XING Li-Na(Department of Radiation Oncology,the Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China;Department of Urology,the First Hospital of Harbin,Harbin 150010,China)

机构地区：[1]哈尔滨医科大学附属二院肿瘤放疗科,哈尔滨150086 [2]哈尔滨市第一医院泌尿外科,哈尔滨150010

出　　处：《中华老年多器官疾病杂志》2018年第9期717-720,共4页Chinese Journal of Multiple Organ Diseases in the Elderly

摘　　要：随着人们对肿瘤免疫研究的深入,免疫检查点抑制剂为代表的免疫治疗在临床试验及实践中获得了满意疗效,但客观缓解率较低,其疗效暂不明确。目前有效预测免疫治疗疗效的标志物一直没有定论。多项临床试验表明肿瘤突变负荷(TMB)与T淋巴细胞识别抗原及免疫疗效呈正相关,可用于预测免疫检查点抑制剂的疗效,但TMB预测免疫治疗疗效尚存在一定的局限性。为此,本文综述了TMB对非小细胞肺癌(NSCLC)免疫治疗疗效的预测价值及目前应用的局限性。As tumor immunology research continues, the clinical trials and application of immunotherapy represented by the immu- nological checkpoint inhibitors have achieved satisfactory results, but its objective response rates are low, and its efficacy remains uncertain. The effectiveness of the markers in predicting the immunotherapy efficacy has been inconclusive. A number of clinical trials have found that tumor mutation burden （TMB） is positively correlated with antigens recognized by T-cells and immunotherapy efficacy. It can be, therefore, used to predict the efficacy of immunological checkpoint inhibitors, but with limitations. This article reviewed the predictive value of TMB in immunotherapy for non-small-cell lung cancer and its limitations.

关 键 词：免疫 治疗 非小细胞肺癌 突变 

分 类 号：R734.2[医药卫生—肿瘤]